Second consensus statement on the diagnosis of multiple system atrophy

By S. Gilman, G. Wenning, Phillip A. Low, D. Brooks, C. Mathias, John Q. Trojanowski, N. Wood, C. Colosimo, A. Durr, C. Fowler and 10 more. Neurology, 2008

3,073 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/cd9f2e5575bb374fcdd8ffdb1476b525a74d2370

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Dennis W. Dickson
2. Daniel H. Geschwind
3. M. Goedert
4. M. Stamelou
5. T. Tomita
6. Lea Teneholz Grinberg

In Neurology

1. Brittany N. Dugger
2. Dennis W. Dickson
3. M. Hasegawa
4. Eduardo Tolosa
5. Chao Gao
6. Shengdi Chen
7. Yuyan Tan
8. Jingwen Jiang

Citations in the corpus

• Pathology of Neurodegenerative Diseases. (2017, background): “In both subtypes, there is significant and often disabling autonomic dysfunction (Gilman et al. 2008).”
• Structures of α-Synuclein Filaments from Multiple System Atrophy (2020, background): “Patients suffer from parkinsonism, cerebellar ataxia and autonomic failure (17-20).”
• The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (2022, methodology): “The second consensus criteria for the diagnosis of MSA have been widely used as a diagnostic reference standard over the past 14 years.(3) Data from two recent clinicopathological series, however, suggest that these have suboptimal accuracy (62%–79%) due to overlapping clinical manifestations with M”
• Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “Diagnostic criteria for DLB and MSA (McKeith et al. 2005; Gilman et al. 2008) Diagnostic criteria for dementia with Lewy bodies (DLB) 1.”
• Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism (2015, background): “The neuropathological diagnosis of MSA required the presence of GCIs (15).”
• Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023, background): “Depending on the predominant symptom, MSA is clinically classified into two subtypes: MSA with predominant cerebellar ataxia (MSA-C) and MSA with predominant parkinsonism (MSA-P), whereas olivopontocerebellar atrophy and striatonigral degeneration represent pathological variants, respectively.(268) ”